Cue Biopharma
CUE
37 hedge funds and large institutions have $40.5M invested in Cue Biopharma in 2019 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 19 increasing their positions, 5 reducing their positions, and 3 closing their positions.
280% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 5
52% more capital invested
Capital invested by funds: $26.7M → $40.5M (+$13.8M)
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
0.17% more ownership
Funds ownership: 0.56% → 0.72% (+0.17%)
3% less funds holding
Funds holding: 38 → 37 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$4.15M |
| 2 |
BlackRock
New York
|
+$1.67M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.28M |
| 4 |
N
Nuveen
Charlotte,
North Carolina
|
+$525K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$489K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
-$292K |
| 2 |
Millennium Management
New York
|
-$86K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$74.8K |
| 4 |
Wells Fargo
San Francisco,
California
|
-$59.7K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$16K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Barclays
London,
United Kingdom
| $105K | +$54K | +217 | +127% |
|
|
AIG
27
American International Group
New York
| $103K | -$995 | -4 | -1% |
|
28
New York State Common Retirement Fund
Albany,
New York
| $97K | +$63.9K | +257 | +250% |
|
29
JP Morgan Chase
New York
| $38K | +$5.22K | +21 | +15% |
|
30
Legal & General Group
London,
United Kingdom
| $20K | – | – | – |
|
31
Bank of Montreal
Toronto,
Ontario, Canada
| $20K | +$12.9K | +52 | +248% |
|
32
BNP Paribas Financial Markets
Paris,
France
| $18.5K | -$14.4K | -58 | -46% |
|
|
DOA
33
D'Orazio & Associates
Falls Church,
Virginia
| $18K | – | – | – |
|
|
AIP
34
Ameritas Investment Partners
Lincoln,
Nebraska
| $14K | – | – | – |
|
|
MAM
35
Meeder Asset Management
Dublin,
Ohio
| $5K | – | – | – |
|
|
LTFS
36
Ladenburg Thalmann Financial Services
Miami,
Florida
| $1K | – | – | – |
|
|
RJA
37
Raymond James & Associates
St Petersburg,
Florida
| – | -$292K | -1,260 | Closed |
|
|
38
Millennium Management
New York
| – | -$86K | -370 | Closed |
|
|
TRCT
39
Tower Research Capital (TRC)
New York
| – | -$16K | -69 | Closed |
|
CUE Hedge Fund Activity: Q2 2019 in Review
37 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Cue Biopharma (CUE) for Q2 2019, worth a combined $40.5M — up 52% from $26.7M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new CUE positions and 3 closed out — a net gain of 1 holder — while 19 added to existing stakes and 5 trimmed.
The largest buyer was Nantahala Capital Management, adding an estimated $4.15M. The largest seller was Raymond James & Associates, exiting entirely with an estimated $292K sold.
- 37 institutional investors held Cue Biopharma (CUE) as of Q2 2019, down from 38 in Q1 2019.
- Funds reported $40.5M of Cue Biopharma stock for Q2 2019, up 52% quarter-over-quarter.
- 4 funds opened new Cue Biopharma positions in Q2 2019 and 3 closed out, a net change of +1 holder.
- The largest Cue Biopharma buyer in Q2 2019 was Nantahala Capital Management, an estimated $4.15M added.
- The largest Cue Biopharma seller in Q2 2019 was Raymond James & Associates, an estimated $292K sold.
Based on aggregated 13F filings for Q2 2019.